Overview

A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
To investigate dose-response of Rapid Acting Intramuscular Olanzapine in Agitated Patients with Schizophrenia
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Olanzapine